About Myovant Sciences (NYSE:MYOV)
Myovant Sciences Ltd. is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for women's health diseases and other endocrine-related disorders. Its main product candidate is Relugolix. Relugolix is an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone (GnRH) receptor antagonist that binds to and inhibits receptors in the anterior pituitary gland. Inhibition of GnRH receptors decreases the release of the gonadotropins, luteinizing hormone, or LH, and follicle-stimulating hormone, or FSH, thereby decreasing the down-stream production of estrogen and progesterone by the ovaries in women and testosterone by the testes in men. It is advancing relugolix for the treatment of heavy menstrual bleeding associated with uterine fibroids, endometriosis-associated pain and prostate cancer. It intends to develop its second product candidate, RVT-602, for the treatment of female infertility as part of assisted reproduction.
Industry, Sector and Symbol:
- Industry: Biopharmaceuticals
- Sub-Industry: N/A
- Sector: Medical
- Symbol: NYSE:MYOV
- Previous Symbol: NASDAQ:MYOV
- CUSIP: N/A
- Web: myovant.com
- Current Ratio: 7.79%
- Quick Ratio: 7.79%
Sales & Book Value:
- Annual Sales: N/A
- Price / Sales: N/A
- Book Value: $2.77 per share
- Price / Book: 4.60
- Trailing EPS: ($1.41)
- Net Income: ($83,440,000.00)
- Return on Equity: -53.75%
- Return on Assets: -48.90%
- Employees: 36
- Outstanding Shares: 60,990,000
Frequently Asked Questions for Myovant Sciences (NYSE:MYOV)
What is Myovant Sciences' stock symbol?
Myovant Sciences trades on the New York Stock Exchange (NYSE) under the ticker symbol "MYOV."
Where is Myovant Sciences' stock going? Where will Myovant Sciences' stock price be in 2017?
6 analysts have issued 1 year price objectives for Myovant Sciences' shares. Their forecasts range from $17.00 to $25.00. On average, they anticipate Myovant Sciences' share price to reach $20.00 in the next twelve months. View Analyst Ratings for Myovant Sciences.
What are Wall Street analysts saying about Myovant Sciences stock?
Here are some recent quotes from research analysts about Myovant Sciences stock:
- 1. According to Zacks Investment Research, "Myovant Sciences Ltd. is a biopharmaceutical company. It focused on developing and commercializing therapies for women's health diseases and other endocrine-related disorders, including advanced prostate cancer. The company's product candidate consists of relugolix which are in clinical trial, an oral once-daily small molecule that acts as a gonadotropin-releasing hormone receptor antagonist. Myovant Sciences Ltd. is based in Hamilton, Bermuda. " (11/17/2017)
- 2. Cowen and Company analysts commented, "Myovant reported a FQ2:18 net loss of $29.9MM and a 9/30 cash balance of." (11/14/2017)
Who are some of Myovant Sciences' key competitors?
Some companies that are related to Myovant Sciences include Horizon Therapeutics (HPTX), Anika Therapeutics (ANIK), Vitae Pharmaceuticals (VTAE), Sinovac Biotech (SVA), 3SBio (SSRX), ChemoCentryx (CCXI), Syros Pharmaceuticals (SYRS), Kadmon Holdings (KDMN), Mereo BioPharma Group plc (MPH), Strongbridge Biopharma PLC (SBBP), Syndax Pharmaceuticals (SNDX), Peregrine Pharmaceuticals (PPHM), Fortress Biotech (FBIO), Kamada (KMDA), Mirna Therapeutics (SYBX), Vericel Corporation (VCEL), MediWound (MDWD) and KalVista Pharmaceuticals (KALV).
Who are Myovant Sciences' key executives?
Myovant Sciences' management team includes the folowing people:
- Lynn Seely M.D., Principal Executive Officer, Director (Age 58)
- Frank L. Karbe, Principal Financial, Accounting Officer (Age 49)
- Marianne L. Romeo, Head, Global Transactions & Risk Management (Age 49)
- Terrie Curran, Director (Age 48)
- Keith S. Manchester M.D., Director (Age 48)
- Vivek Ramaswamy, Director (Age 31)
- Mark Altmeyer, Independent Director (Age 56)
- Wayne S. DeVeydt, Independent Director (Age 47)
When did Myovant Sciences IPO?
(MYOV) raised $176 million in an initial public offering on Thursday, October 27th 2016. The company issued 13,000,000 shares at $12.00-$15.00 per share. Citigroup, Cowen and Company, Evercore ISI and Barclays served as the underwriters for the IPO and JMP Securities and Baird were co-managers.
Who owns Myovant Sciences stock?
Myovant Sciences' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include
SVF INVESTMENTS (UK) LTD
(61.20%), JPMorgan Chase & Co. (0.15%), Point72 Asset Management L.P. (0.13%) and OxFORD Asset Management LLP (0.04%). View Institutional Ownership Trends for Myovant Sciences.
Who sold Myovant Sciences stock? Who is selling Myovant Sciences stock?
Who bought Myovant Sciences stock? Who is buying Myovant Sciences stock?
How do I buy Myovant Sciences stock?
Shares of Myovant Sciences can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Myovant Sciences' stock price today?
One share of Myovant Sciences stock can currently be purchased for approximately $12.75.
How big of a company is Myovant Sciences?
Myovant Sciences has a market capitalization of $790.4 million. The company earns ($83,440,000.00) in net income (profit) each year or ($1.41) on an earnings per share basis. Myovant Sciences employs 36 workers across the globe.
How can I contact Myovant Sciences?
Myovant Sciences' mailing address is 11-12 ST. JAMES SQUARE, LONDON X0, SW1Y 4LB. The company can be reached via phone at 203-318-9709 or via email at [email protected]
MarketBeat Community Rating for Myovant Sciences (NYSE MYOV)MarketBeat's community ratings are surveys of what our community members think about Myovant Sciences and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Analysts' Consensus Rating for Myovant Sciences (NYSE:MYOV) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus analyst ratings for company stocks using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||0 Sell Ratings, 0 Hold Ratings, 6 Buy Ratings, 0 Strong Buy Ratings|
|Consensus Rating:||Buy (Score: 3.00)|
|Consensus Price Target: ||$20.00 (56.86% upside)|
Consensus Price Target History for Myovant Sciences (NYSE:MYOV)
Analysts' Ratings History for Myovant Sciences (NYSE:MYOV)
(Data available from 11/20/2015 forward)
|Date||Firm||Action||Rating||Price Target||Impact on Share Price||Details|
|11/14/2017||Cowen and Company||Reiterated Rating||Buy||N/A|
|11/10/2017||Robert W. Baird||Reiterated Rating||Buy||$20.00||N/A|
|10/4/2017||JMP Securities||Reiterated Rating||Outperform||$23.00 -> $25.00||Low|
|8/16/2017||Evercore ISI||Initiated Coverage||Outperform -> Outperform||High|
|11/21/2016||Citigroup Inc.||Initiated Coverage||Buy||$17.00||N/A|
|11/21/2016||Barclays PLC||Initiated Coverage||Overweight||$18.00||N/A|
Earnings History for Myovant Sciences (NYSE:MYOV)
No earnings announcements for this company have been tracked by MarketBeat.com
Earnings Estimates for Myovant Sciences (NYSE:MYOV)
Current Year EPS Consensus Estimate: $-1.74 EPS
Next Year EPS Consensus Estimate: $-1.95 EPS
Dividend History for Myovant Sciences (NYSE:MYOV)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading History for Myovant Sciences (NYSE MYOV)
No insider trades for this company have been tracked by MarketBeat.com
Latest Headlines for Myovant Sciences (NYSE MYOV)
Myovant Sciences (NYSE MYOV) Chart for Monday, November, 20, 2017